The Impact of Oral Contrast in Multidetector CT of the Abdomen and Pelvis on Radiologist Confidence

NCT ID: NCT01655550

Last Updated: 2012-08-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

216 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-30

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators seek to demonstrate the non-superiority of oral contrast versus no oral contrast in intravenously enhanced CT in the outpatient setting. The investigators want to decrease preparation time for the patient and decrease delay in obtaining the study which will ultimately lead to faster results and an increased level of patient convenience.

The investigators hypothesis: Oral contrast does not significantly affect the diagnostic confidence of interpreting radiologists in intravenously enhanced abdominal CT scans.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be a randomized controlled trial comparing radiologist confidence when faced with an intravenously enhanced study with and without oral contrast. At the time of making the appointment, the clerk will ask the patient if he/she wishes to participate in a research study about the impact of oral contrast. If the patient assents, he/she will receive a phone call from a research assistant to obtain informed consent. The first ten patients to call the office to schedule a scan using a 64 slice MDCT will be recruited and randomized if they consent.

Subjects will be randomized at the time of recruitment, which will be when he/she calls to make the appointment for the exam, in a 1:1 ratio between the control arm (contrast) and the experimental arm (no contrast). The control arm will either pick up their two bottles of oral contrast at a radiology office or have the bottles mailed to them as is currently the standard. They will drink the oral contrast two hours before the study. They will also ingest 300 mL of water immediately prior to imaging and be administered the standard intravenous contrast dose. The experimental group will not be mailed or given any oral contrast. They will arrive at their appointment and ingest 300 mL of water immediately prior to the exam as well as the standard intravenous contrast dose and be scanned. This design will eliminate the need to repeat scanning patients, thus decreasing radiation dose. A patient satisfaction survey will be given to each patient following the exam and handed to the technologist

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Routine Outpatients Undergoing Contrast Enhanced CT Scan of the Abdomen and Pelvis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of Care

Patients will get routine CT scans with Oral and Intravenous contrast prior to their CT scan as is routine, standard practice

Group Type OTHER

Withhold oral contrast

Intervention Type OTHER

The intervention is to withhold oral contrast

Withold Oral Contrast

Subjects will not drink oral contrast, but instead water (in itself a type of contrast agent) prior to their CT. Intravenous contrast will be administered as is routine

Group Type EXPERIMENTAL

Withhold oral contrast

Intervention Type OTHER

The intervention is to withhold oral contrast

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Withhold oral contrast

The intervention is to withhold oral contrast

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* order for "Contrast Enhanced abdomen CT" or "Contrast Enhanced abdomen/pelvis CT"

* age ≥21
* able and willing to give consent

Exclusion Criteria

* • allergy to IV contrast

* order for non-contrast CT
* \<21
* pregnant woman
* order for enterography or colonography
* history of Crohn's Disease or Ulcerative Colitis
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hartford Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christopher M Garcia, MD MHS

Role: PRINCIPAL_INVESTIGATOR

Hartford Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jefferson Radiology

Hartford, Connecticut, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chris Garcia, MD MHS

Role: CONTACT

Phone: 860 545 5240

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Bret Coughlin, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GARC003501

Identifier Type: -

Identifier Source: org_study_id